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Poly(lactic-co-glycolic acid) (PLGA) is currently the most widely used biomaterial for 
encapsulation and prolonged delivery of therapeutic drugs, proteins and antigens [1]. We 
introduce originally synthesized branched PLGA derivatives with lower molar mass, and star 
or comb architecture as promising biodegradable carriers for prolonged or targeted drug 
release systems [2]. These polyesters were used as starting materials for nanoparticles 
formulation by nanoprecipitation, and double-emulsion method. We successfully 
incorporated various molecules such as Terbinafine, Rifampicin, and Small interfering RNA 
(siRNA). Multiple parameters as particles size, polydispersity, zeta potential, encapsulation 
efficiency, and loading capacity were monitored. Morphology of the nanoparticles was 
studied by scanning electron microscope (SEM). The use of the polymers with tailored 
properties resulted in formulation of the nanoparticles with desired particle size, 
mucoadhesive properties, and prolonged drug release profile which we attribute to the 
gradual swelling and degradation of the polyester in an aqueous medium [3]. The 
hydrophobicity and the polyester concentration revealed the main impact on the 
nanoparticles size ranging from 100 to 600nm [4]. Examined polyesters are perspective, 
original, and suitable for further observation. 
 
References 
1. Han F. Y. et al. Front. Pharmacol. 7:185, (2016) 
2. Snejdrova E. et al. Acta Pharm. 70, 63-75 (2020) 
3. Dittrich M. et al. J. Pharm. Sci. 103, 3560-3566 (2014) 
4. Martiska J. et al. Pharm. Dev. Technol. 24(10), 1308-1316 (2019) 
 
Supervisor(s): Assoc. Prof. RNDr. Milan Dittrich, CSc; PharmDr. Eva Snejdrova, PhD. 
 
Acknowledgement 
This work was supported by the Funding Agency of Charles University under Grant SVV 
260401. 
 
  
DOI: 10.14232/syrptbrs.2020.op4 
 
